Polynovo Ltd. is an Australian pharmaceutical company with a focus on sustainability and governance. With an ESG score of 29.8, the company is at a medium risk level. Polynovo's main revenue comes from sales in the US of its innovative product, NovoSorb Biodegradable Temporizing Matrix (BTM). This patented synthetic scaffold is designed to aid in the regeneration of dermis lost due to surgery, trauma, burns, or other causes of tissue loss. Once applied to a wound, the NovoSorb BTM integrates with the dermal layer over a few weeks before outer layers can be removed by a clinician. Small wounds can heal naturally or with a dressing, while larger wounds may require a split-skin graft. The NovoSorb BTM then degrades over time to harmless byproducts that are fully absorbed within 18 months.